1-3 of 3
Florian Voss
Close
Sort by
Journal Articles

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Clinical Trials & Observations
Hartmut Döhner, Michael Lübbert, Walter Fiedler, Loic Fouillard, Alf Haaland, Joseph M. Brandwein, Stephane Lepretre, Oumedaly Reman, Pascal Turlure, Oliver G. Ottmann, Carsten Müller-Tidow, Alwin Krämer, Emmanuel Raffoux, Konstanze Döhner, Richard F. Schlenk, Florian Voss, Tillmann Taube, Holger Fritsch, Johan Maertens
Journal: Blood
Blood (2014) 124 (9): 1426–1433.
https://doi.org/10.1182/blood-2014-03-560557
Published: 2014
Includes: Supplemental data
Journal Articles

Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment

Johan Maertens, MD, PhD, Michael Lübbert, MD, Walter Fiedler, MD, Loic Fouillard, Alf Haaland, MD, Joseph M. Brandwein, MD, Stéphane Lepretre, MD, Oumédaly Reman, MD, Pascal Turlure, MD, Gesine Bug, Carsten Müller-Tidow, Alwin Krämer, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Hartmut Döhner, MD
Journal: Blood
Blood (2012) 120 (21): 411.
https://doi.org/10.1182/blood.V120.21.411.411
Published: 2012
Journal Articles

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Gesine Bug, MD, Carsten Müller-Tidow, MD, Richard F Schlenk, MD, Alwin Krämer, MD, Michael Lübbert, MD, PhD, Utz Krug, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Pilar Garin-Chesa, MD, PhD, Oliver G Ottmann, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2011) 118 (21): 1549.
https://doi.org/10.1182/blood.V118.21.1549.1549
Published: 2011